DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on September 29, 2008; DOI: 10.1124/dmd.108.022418


0090-9556/09/3701-143-149$20.00
DMD 37:143-149, 2009

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.108.022418v1
37/1/143    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knütter, I.
Right arrow Articles by Brandsch, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knütter, I.
Right arrow Articles by Brandsch, M.

High-Affinity Interaction of Sartans with H+/Peptide Transporters

Ilka Knütter, Gabor Kottra, Wiebke Fischer, Hannelore Daniel, and Matthias Brandsch

Membrane Transport Group, Biozentrum of the Martin-Luther-University Halle-Wittenberg, Halle, Germany (I.K., W.F., M.B.); and Molecular Nutrition Unit, Center of Life and Food Science, Technical University of Munich, Freising-Weihenstephan, Germany (G.K., H.D.)

Sartans are very effective drugs for treatment of hypertension, heart failure, and other cardiovascular disorders. They antagonize the effects of angiotensin II at the AT1 receptor and display p.o. bioavailability rates of 13 to 80%. Because some sartans sterically resemble dipeptide derivatives, we investigated whether they are transported by peptide transporters. We first assessed the effects of sartans on [14C]glycylsarcosine uptake into Caco-2 cells expressing H+/peptide transporter (PEPT) 1 and into SKPT cells expressing PEPT2. Losartan, irbesartan, valsartan, and eprosartan inhibited [glycine-1-14C]glycylsarcosine ([14C]Gly-Sar) uptake into Caco-2 cells in a competitive manner with Ki values of 24, 230, 390, and >1000 µM. Losartan and valsartan also strongly inhibited the total transepithelial flux of [14C]Gly-Sar across Caco-2 cell monolayers. In SKPT cells, [14C]Gly-Sar uptake was inhibited with Ki values of 2.2 µM (losartan), 65 µM (irbesartan), 260 µM (valsartan), and 490 µM (eprosartan). We determined by the two-electrode voltage-clamp technique whether the compounds elicited transport currents by PEPT1 or PEPT2 when expressed in Xenopus laevis oocytes. No currents were observed for any of the sartans, but the compounds strongly and reversibly inhibited peptide-induced currents. Uptake of valsartan, losartan, and cefadroxil was quantified in HeLa cells after heterologous expression of human PEPT1 (hPEPT1). In contrast to cefadroxil, no PEPT1-specific uptake of valsartan and losartan was found. We conclude that the sartans tested in this study display high-affinity interaction with PEPTs but are not transported themselves. However, they strongly inhibit hPEPT1-mediated uptake of dipeptides and cefadroxil.


Address correspondence to: Dr. Matthias Brandsch, Biozentrum of the Martin-Luther-University Halle-Wittenberg, Membrane Transport Group, Weinbergweg 22, D-06120 Halle, Germany. E-mail: matthias.brandsch{at}biozentrum.uni-halle.de







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2009 by the American Society for Pharmacology and Experimental Therapeutics.